Edition:
India

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

12.97USD
25 Sep 2020
Change (% chg)

$0.42 (+3.35%)
Prev Close
$12.55
Open
$12.40
Day's High
$13.26
Day's Low
$12.40
Volume
290,347
Avg. Vol
442,332
52-wk High
$19.36
52-wk Low
$4.52

Renaud, Ronald 

Mr. Ronald C. Renaud Jr. serves as Chairman of the Board of the Company. Ron has served as Translate Bio's chief executive officer since 2014. Formerly, Ron was at Idenix Pharmaceuticals, an innovative company in the field of viral human diseases where he served as chief financial officer, chief business officer and finally, president and chief executive officer. Under his leadership, Idenix refocused its drug-discovery and development efforts and streamlined operations prior to the Merck acquisition for approximately $3.85 billion in August 2014. Prior to joining Idenix, Ron served as executive vice president and chief financial officer of Keryx Biopharmaceuticals. Before joining Keryx, Ron was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. He serves on the board of directors of Translate Bio, Ikena Oncology and Axial Biotherapeutics.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --